andexanet alfa   

GtoPdb Ligand ID: 7576

Synonyms: Andexxa® | coagulation factor Xa (recombinant), inactivated-zhzo | Ondexxya® | PRT064445 | PRT4445 | r-antidote
andexanet alfa is an approved drug (FDA (2018), EMA (2019))
Comment: Andexanet alfa is a recombinant modified human Factor Xa (FXa) protein that acts as a mimetic of endogenous human factor Xa, and which was developed as a universal antidote to reverse thhe anticoagulant effects of direct or indirect FXa inhibitors. Information regarding the invention of andexanet alfa is available in patent WO2009042962 [2].
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: andexanet alfa

References
1. Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P, Hutchaleelaha A, Inagaki M, Conley PB et al.. (2013)
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa.
Nat. Med., 19 (4): 446-51. [PMID:23455714]
2. Lu G, Phillips DR, Andre P, Sinha U. (2009)
Antidotes for factor xa inhibitors and methods of using the same.
Patent number: WO2009042962 A2. Assignee: Portola Pharm Inc and Inventors.. Priority date: 28/08/2007. Publication date: 02/04/2009.
3. Rogers KC, Finks SW. (2019)
A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors: Andexanet Alfa (ANDEXXA).
Am. J. Med., 132 (1): 38-41. [PMID:30053385]
4. Shaw JR, Siegal DM. (2018)
Pharmacological reversal of the direct oral anticoagulants-A comprehensive review of the literature.
Res Pract Thromb Haemost, 2 (2): 251-265. [PMID:30046727]